Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 210
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data
Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts
Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast
BREAKING: Second Positive Phase 3 for Compass’ Psilocybin, Though Modest Magnitude Raises Questions
AtaiBeckley Seeks Partner for BPL-003 as Pharma Interest Builds After AbbVie-Gilgamesh Deal
Editor’s Choice Award 2021-Best Study on Psychedelics and Neurochemistry
Ibogaine and Cardiac Arrhythmia: The Heart of the Matter
PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening...
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals...
Wesana Health Reports Q3 2021 Financial Results
Awakn Life Sciences Strengthens Executive Leadership Team
PT275 – James Fadiman, Ph.D. – Transpersonal Psychology, Microdosing, and Your...
MindMed and Liechti Lab publish first human data on the interacting...
Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic...
MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation
Load more